[French Expert advice on the management of valproate in childbearing and pregnant women with bipolar disorder].
Fiche publication
Date publication
octobre 2022
Journal
L'Encephale
Auteurs
Membres identifiés du Cancéropôle Est :
Pr HAFFEN Emmanuel
Tous les auteurs :
Samalin L, Arnould A, Boudieu L, Henry C, Haffen E, Drapier D, Anmella G, Pacchiarotti I, Vieta E, Belzeaux R, Llorca PM
Lien Pubmed
Résumé
The perinatal period is associated with high risk of relapses in women with untreated bipolar disorder (BD) and can have significant consequences on foetal and child development. Valproate is an effective mood stabilizer in BD but it is also the anticonvulsant associated to the highest risks of neurodevelopmental disorders and congenital malformations. The National Agency for the Safety of Medicines and Health Products (ANSM) changed the conditions of use and prescription of valproate in France in 2015. Its prescription is now contraindicated (i.e., not to be prescribed) in women able to have children unless alternative treatments are ineffective or not tolerated. Moreover, valproate could only be prescribed if the protocol of a specific pregnancy prevention program is followed.
Mots clés
Bipolar disorder, Childbearing, Femme en âge de procréer, Guidelines, Perinatal, Périnatalité, Recommandations professionnelles, Trouble bipolaire, Valproate
Référence
Encephale. 2022 10 15;: